Dr Alastair Smith, chief executive of Avacta, speaks to ProactiveInvestors Stocktube about the potential of Affimer technology, which is being used to develop diagnostic tests for the Zika virus, which causes crippling birth defects.
Avacta realised the huge potential of the technology when it bought the IP in 2012 and is now quickly building awareness of its potential to create both diagnostic and therapeutic (drug) products.